Advanced search
Publication Cover
Leukemia & Lymphoma Volume 23, 1996 - Issue 1-2
Submit an article Journal homepage
13
Views
1
CrossRef citations to date
0
Altmetric
Original Article

Etoposide and Mitoxantrone as a Second Cycle of Consolidation Therapy Following High Dose Cytosine Arabinoside and Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia in Remission: A Pilot Study

Richard S. Stein Division of Hematology and the Bone Marrow Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
John P. Greer Division of Hematology and the Bone Marrow Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
John M. Flexner Division of Hematology and the Bone Marrow Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA
,
Stacey Goodman Division of Hematology and the Bone Marrow Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA
&
Steven N. Wolff Division of Hematology and the Bone Marrow Transplant Program, Vanderbilt University Medical Center, Nashville, Tennessee, USA
Pages 93-98 | Received 20 Jul 1995, Accepted 01 Dec 1995, Published online: 01 Jul 2009

References

  • Wolff S. N., Marion J., Stein R. S., et al. High-dose cyto-sine arabinoside and daunorubicin as consolidation therapy for acute non-lymphocytic leukemia in first remission: A pilot study. Blood 1985; 65: 1407–1411
  • Wolff S. N., Herzig R. H., Phillips G. L., et al. High-dose cytosine arabinoside and daunorubicin as brief consolidation therapy for acute non-lymphocytic leukemia in first remission: An update. Semin. Oncol. 1987; 14(suppl 2)12–17
  • Wolff S. N., Herzig R. H., Fay J. W., et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J. Clin. Oncol. 1989; 7: 1260–1267
  • Preisler H. D., Raza A., Early A., et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J. Clin. Oncol. 1987; 5: 722–730
  • Tricot G., Boogaerts M. A., Vlietinck R., et al. The role of intensive remission induction and consolidation therapy in patients with acute myeloid leukaemia. Br. J. Haematol. 1987; 66: 37–44
  • Harousseau J. L., Milpied N., Briere J., et al. Double intenisve consolidation chemotherapy in adult acute leukemia. J. Clin. Oncol. 1991; 9: 1432–1437
  • Cassileth P. A., Lynch E., Hines J. D., et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992; 79: 1924–1930
  • Schiller G., Gajewski J., Territo M., et al. Long term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977–2982
  • Mayer R. J., Davis R. B., Schiffer C. A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N. Engl. J. Med. 1994; 331: 896–903
  • Bloomfield C. D., Lawrence D., Arthur D. C., et al. Curative impact of intensification with high-dose cytarabine in acute myeloid leukemia varies by cytogenetic group. Blood 1994; 84(Suppl 1)111a, (abstract)
  • Goodman S., Greer J. P., Stein R. S., et al. Extended VP16 administration for the treatment of acute leukemia. Phase I/II studies (abstract). Proc. Am. Soc. Clin. Oncol. 1994; 13: 311
  • Hainsworth J. D., Johnson D. H., Frazier S. R., et al. Chronic daily administration of oral etoposide—a phase I trial. J. Clin. Oncol. 1989; 7: 396–401
  • Johnson D. H., Greco F. A., Strupp J., et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J. Clin. Oncol. 1990; 8: 1613–1617
  • Bennett J. M., Catovsky D., Daniel M. T., et al. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British cooperative Group. Ann. Intern. Med. 1985; 103: 620–625
  • Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–481
  • Peto R., Pike M. C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer 1977; 35: 1–39
  • Oken M. M., Creech R. H., Tormey D. C., et al. Toxicity and response criterion of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–652
  • List A. F., Spier C., Greer J., et al. Phase I/TI trial of cyclosporin as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 1993; 11: 1652–1660
  • Appelbaum F. R., Fisher L. D., Thomas E. D. Chemotherapy v bone marrow transplantation for adults with acute nonlymphocytic leukemia: A 5-year follow-up. Blood 1988; 72: 179–184
  • Champlin R. E., Ho W. G., Gale R. P., et al. Treatment of acute myelogenous leukemia. A prospectively controlled trial of bone marrow transplantation versus consolidation chemotherapy. Ann. Intern. Med., 102: 285–291
  • Clift R. A., Buckner C. D., Appelbaum F. R., et al. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J. Clin. Oncol., 10: 1723–1729
  • Brown R. A., Wolff S. N., Fay J. W., et al. High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse. A study of the North American Bone Marrow Transplant Group. Blood 1995; 85: 1391–1395
  • Yeager A. M., Kaizer H., Santos G. W., et al. Autologous bone marrow transplantation in patients with acute non-lymphoblastic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N. Engl. J. Med. 1986; 315: 141–147
  • Meloni G., Foa R., Vignetti M., et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84: 2158–2163

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.